Vifor Pharma AG (OTCMKTS:GNHAF – Get Rating) saw a large growth in short interest during the month of May. As of May 15th, there was short interest totalling 11,700 shares, a growth of 1,571.4% from the April 30th total of 700 shares. Based on an average daily trading volume, of 0 shares, the days-to-cover ratio is presently ∞ days.
GNHAF stock remained flat at $$173.25 during midday trading on Wednesday. Vifor Pharma has a 12 month low of $112.75 and a 12 month high of $183.50. The business’s fifty day moving average is $174.87 and its 200 day moving average is $160.17.
Separately, UBS Group boosted their price objective on Vifor Pharma from CHF 167 to CHF 179 in a research report on Tuesday, May 17th.
Vifor Pharma AG, a pharmaceutical company, focuses on the development, manufacture, and commercialization of pharmaceutical products in Switzerland, rest of Europe, the United States, and internationally. The company offers Ferinject/Injectafer, a solution of ferric carboxymaltose used for the treatment of iron deficiency and iron deficiency anemia; Maltofer, an oral iron polymaltose complex for infants, children, adolescents, and pregnant woman with iron deficiency; and Mircera, a long-acting erythropoiesis-stimulating agent (ESA) to treat symptomatic anemia associated with the chronic kidney disease (CKD).It also provides Retacrit, a short-acting ESA; Venofer, an intravenous iron sucrose used in the intravenous treatment of iron deficiency; and Velphoro, a non-calcium, iron-based chewable phosphate binder for the treatment of hyperphosphatemia in adults with CKD undergoing dialysis.
- Get a free copy of the StockNews.com research report on Vifor Pharma (GNHAF)
- Short-Covering Begins In Big Lots
- Institutions Ring The Register On Toll Brothers Stock
- Agilent Technologies Is Bottoming But Don’t Buy It Yet
- Dick’s Sporting Goods Falls Flat On Weak Guidance
- Two Retailers, One To Buy And One To Avoid
Receive News & Ratings for Vifor Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vifor Pharma and related companies with MarketBeat.com's FREE daily email newsletter.